Danone S.A.

Danone reported Q2 like-for-like sales growth of 4.2% and H1 like-for-like sales growth of 3.5%. Reported Q2 sales were EUR 7.2 billion, up 4.4%, with currency at minus 1% and scope contributing plus 0.8%. H1 recurring operating margin was 13.3%, up 12 basis points year over year; recurring EPS was EUR 1.92, up 0.9%; and free cash flow was EUR 0.9 billion. Management confirmed full-year 2026 guidance of 3% to 5% like-for-like sales growth and recurring operating income growth faster than sales.

Antoine de Saint-Affrique framed the quarter as another set of “solid high-quality results” and emphasized that Danone’s health-focused portfolio and multi-engine growth model are working in a “challenging and volatile” environment. He highlighted strong momentum in high-protein dairy, Skyr, kefir, plant-based innovation, and medical nutrition, while acknowledging North America still needs sequential fixes and that IMF in EMEA is still normalizing. His tone was upbeat but disciplined, repeatedly stressing “constructive dissatisfaction,” execution, and selective M&A.

Juergen Esser emphasized broad-based Q2 growth across regions and categories, with EDP up 3.8%, specialized nutrition up 4.5%, and waters up 4.7%. He cited 1.9% volume/mix contribution in Q2, plus 0.8% scope from Kate Farms and the Australian dairy JV, and noted that free cash flow of EUR 0.9 billion was held back by temporary security stock increases. He said H1 margin was pressured by the IMF recall and commodity inflation, partially offset by productivity and efficiency gains, and reiterated that selective price increases should help margins later in the year.

Analysts focused on the pace of the North America turnaround, the slowdown in CNAO volume/mix, cash flow and inventory buildup, EDP margin pressure, and the outlook for China specialized nutrition. Management said North America is improving as capacity comes back line by line, with protein performing well and the rest of the portfolio reactivating gradually; they also said Mizone/waters caused volatility in CNAO while IMF and medical nutrition remain strong. On cash and margins, management said the inventory build was temporary, CapEx is up by about EUR 40 million to EUR 50 million in the semester, and EDP margins should improve as pricing catches up with inflation; on China, they described volume-based purchasing as business as usual and said market shares are well oriented.